Back to search results
NCT07583342

Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis

Enrolling by Invitation
PHASE4Ages 18+InterventionalTreatment
Northwell Health
~15 participants
Updated 2026-05-13 on ClinicalTrials.gov
What's tested:RELiZORB digestive enzyme (immobilized lipase) cartridge

At a glance

Recruiting sites
0 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent of goal nutrition delivered at 72 hours
Measured over From enrollment to the end of treatment at 72 hours

Conditions

Acute Pancreatitis (AP)
Enhancing Enteral Nutrition Tolerance

Explore related trials

Acute Pancreatitis

Where it's being run

5 sites across 1 states
New York5

Study leadership

  • Laura Hansen, MD · PRINCIPAL_INVESTIGATOR · Northwell Health
  • Rafael Barrera, MD · PRINCIPAL_INVESTIGATOR · Northwell Health

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female aged 18 + years of age
Admission to the Surgical Intensive Care Unit in the Northwell Health hospital system
Moderate to severe acute pancreatitis based on Atlanta criteria
Inability to tolerate ≥75% of goal EN (25 kcal/kg/d)

Exclusion

Moribund patients expected to expire within 120 hours
Evidence of unresolved intestinal obstruction, ischemia, bleeding, perforation, fistulas or tract discontinuity, or other contraindication for enteral nutrition
Diagnosis or evidence of C. Difficile or other gastrointestinal infection that may manifest with diarrhea
Pre-existing constipation defined as laxative or stool softener use prior to admission to the hospital
Patients receiving cancer-related treatment in the last 3 months
History of cystic fibrosis
Any other reason that the treating or investigator team considers to be a contraindication to enteral nutrition

What this trial measures

  • Percent of goal nutrition delivered at 72 hoursFrom enrollment to the end of treatment at 72 hours

    Change from baseline in percentage of goal enteral nutrition (kcal/kg/day) received 3 days (72 hours) following initiation of RELiZORB. Baseline is considered the 24 hours prior to RELiZORB start.